Tuesday October 20, 08:26 AM
BRIEF-Almirall says to announce positive lung drug data
Oct 20 (Reuters) - Almirall SA:
* Completion with positive outcome of a short-term Phase II study comparing Eklira (aclidinium) twice daily (BID) vs tiotropium and placebo
* Completion of the enrolment of a larger Phase III three-month study with two different BID doses of Eklira vs placebo in patients with moderate to severe COPD
* Almirall (Madrid: ALM.MC - news) and Forest Laboratories plan to disclose the results of both the short-term comparative Phase II study and the ongoing three-month Phase III study in the first quarter of 2010
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters (LSE: RUT.L - news) .
NNNN
|
|
|
Send Article by Email
Send Article by IM
Blog This with Y! 360
Printable View
